
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NEXTSTELLIS | Mayne Group | N-214154 RX | 2021-04-15 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| nextstellis | New Drug Application | 2023-05-11 |
Expiration | Code | ||
|---|---|---|---|
DROSPIRENONE / ESTETROL, NEXTSTELLIS, MAYNE PHARMA | |||
| 2026-04-15 | NCE | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Drospirenone / Estetrol, Nextstellis, Mayne Pharma | |||
| 7732430 | 2025-03-02 | DP | U-3152 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | — | — | — | — | 2 | 2 |
| Drug common name | Estetrol |
| INN | estetrol |
| Description | Estetrol is a 3-hydroxy steroid that is 17beta-estradiol which has been substituted at the 15alpha and 16alpha positions by two additional hydroxy groups. It is a natural estrogen produced exclusively during pregnancy by the fetal liver. It has a role as an estrogen, an estrogen receptor agonist, a human metabolite, a human xenobiotic metabolite and an oral contraceptive. It is a 3-hydroxy steroid, a 17beta-hydroxy steroid, a 16alpha-hydroxy steroid, a 15alpha-hydroxy steroid and a steroid hormone. It derives from a hydride of an estrane. |
| Classification | Small molecule |
| Drug class | - |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O |
| PDB | — |
| CAS-ID | 15183-37-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1230314 |
| ChEBI ID | — |
| PubChem CID | 27125 |
| DrugBank | DB12235 |
| UNII ID | ENB39R14VF (ChemIDplus, GSRS) |

